Healthspan taxonomy seed — see taxonomy_path
Current stock research snapshot · 8/16/26 10 days old
VKTXViking Therapeutics
Investment conviction●●○○○2 of 5 · current snapshot
Research target$71.19Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 8/16/26
Market cap$3.80BSnapshot value · 8/16/26
Viking Therapeutics Q2 2026 earnings; VK2735 (oral/subcut) obesity Ph2 data timeline; VK2809 (NAFLD/NASH) program update; metabolic pipeline advancement
Thesis breaks if orforglipron (oral small molecule) launches before VK2735 oral Phase 3 (me-too risk on unpatented dual agonism), September maintenance-study misses, or $500M ATM (07/30/26) signals distressed pre-data raise. (vault 2026-08)
Bullish — $VKTX triple tops described as 'made to be broken' (Aug 25). [X search Aug 2026]
Snapshot · 8/16/26🟢 Lean-Bull · ins+$0.1M(1buy) · 13F 16+/8-×0.5 · short↑0.26
Snapshot · 8/16/26